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Abstract
Background: Systemic lupus erythematosus (SLE) is a common systemic autoimmune disease with a complex
genetic inheritance. Genome-wide association studies (GWAS) have significantly increased the number of significant
loci associated with SLE risk. To date, however, established loci account for less than 30% of the disease heritability
and additional risk variants have yet to be identified. Here we performed a GWAS followed by a meta-analysis to
identify new genome-wide significant loci for SLE.
Methods: We genotyped a cohort of 907 patients with SLE (cases) and 1524 healthy controls from Spain and
performed imputation using the 1000 Genomes reference data. We tested for association using logistic regression
with correction for the principal components of variation. Meta-analysis of the association results was subsequently
performed on 7,110,321 variants using genetic data from a large cohort of 4036 patients with SLE and 6959
controls of Northern European ancestry. Genetic association was also tested at the pathway level after removing
the effect of known risk loci using PASCAL software.
Results: We identified five new loci associated with SLE at the genome-wide level of significance (p < 5 × 10− 8): GRB2,
SMYD3, ST8SIA4, LAT2 and ARHGAP27. Pathway analysis revealed several biological processes significantly associated
with SLE risk: B cell receptor signaling (p = 5.28 × 10− 6), CTLA4 co-stimulation during T cell activation (p = 3.06 × 10− 5),
interleukin-4 signaling (p = 3.97 × 10− 5) and cell surface interactions at the vascular wall (p = 4.63 × 10− 5).
Conclusions: Our results identify five novel loci for SLE susceptibility, and biologic pathways associated via multiple
low-effect-size loci.
Keywords: Systemic lupus erythematosus, Genetic susceptibility, Genome-wide association study, Meta-analysis,
Biological pathway analysis
* Correspondence: toni.julia@vhir.org; sara.marsal@vhir.org
1Rheumatology Research Group, Vall d’Hebron Research Institute, 08035
Barcelona, Spain
Full list of author information is available at the end of the article
© The Author(s). 2018 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Julià et al. Arthritis Research & Therapy  (2018) 20:100 
https://doi.org/10.1186/s13075-018-1604-1
Background
Systemic lupus erythematosus (SLE [MIM: 152700]) is a
common systemic autoimmune disease characterized by
the production of autoantibodies and a complex genetic
inheritance. The prevalence of the disease varies according
to the population ancestry, with European populations
ranging between 30 and 90 cases per 100,000 individuals
[1]. SLE afflicts women at a rate nine times higher than
men, and most often appears during childbearing ages.
Concordance rate studies in monozygotic and dizygotic
twins and recurrence risk estimates in siblings of probands
(λs), have clearly shown the importance of genetic factors
in the development of the disease [2].
Despite the evidence for a strong genetic contribution,
until recently, very few loci were convincingly associated
with SLE risk [3]. With the concurrent identification of
common genome variation and the development of
genome-wide genotyping technologies, genome-wide as-
sociation studies (GWAS) have dramatically changed the
ability to identify risk variants. In SLE, GWAS have
allowed the identification of more than 50 risk loci at
a genome-wide significance level (p value <5 × 10− 8)
[4–6]. These findings are of great relevance since they
pinpoint specific biological mechanisms that are
relevant for the disease and that otherwise would not
have been prioritized for research [7]. In a severe
disease like SLE that is lacking efficacious treatments,
genetic studies provide a unique way to expand the
number of molecular targets for drug discovery [8].
To date, the explanation for the inherited risk of SLE
is largely unresolved. Including all known risk variants,
less than 30% of disease heritability is currently
accounted for [9], In order to identify additional risk
variants, GWAS meta-analyses from different countries
have proven to be a highly successful approach [9]. Cur-
rently, most Southern European populations have been
underrepresented in GWAS of SLE. In Spain, epidemio-
logical studies have shown that there is an increased
prevalence of the disease compared to other European
regions [1]. Consequently, the analysis of the genetic
variation in this population could be highly useful to
identify new genetic variation for SLE risk.
Biological pathways integrate the function of multiple
genes and, therefore, provide a higher level of detection
of the relevant genetic risk [10, 11]. To date, different
statistical methods have been developed that exploit the
biological knowledge in order to leverage the power of
GWAS. These analysis methods are designed to aggre-
gate the genetic evidence from multiple risk loci into a
single association statistic. The use of cumulative evidence
can be a powerful way to detect genetic associations and
biological mechanisms that otherwise would have been
missed due to low effect size at the single-marker level.
Using this complementary GWAS approach, relevant
biological insights have been gained in different complex
diseases, including autoimmune diseases [12].
The aim of the current work was to identify new
genetic risk loci for SLE by a GWAS meta-analysis
using a case-control cohort from a previously untar-
geted population. After excluding known risk genes,
pathway meta-analysis was also performed to identify
biologic pathways for SLE risk associated by risk loci
as yet unaccounted for.
Methods
Study cohorts
Patients and controls from the Spanish population were
recruited through the Immune-Mediated Inflammatory
Disease (IMID) Consortium [13]. Patients with SLE were
recruited via the rheumatology departments of 17 uni-
versity hospitals in Spain. All included patients fulfilled
the 1982 revised American College for Rheumatology
diagnosis criteria for SLE [14]. All patients were > 16 years
old at the time of recruitment, although disease could
have started earlier. A minimal disease evolution period of
3 years since diagnosis was also required for inclusion in
this study. All Patients with SLE were Caucasian with all
four grandparents born in Spain. Patients with an add-
itional rheumatologic disease (e.g. rheumatoid arthritis,
systemic sclerosis or mixed connective tissue disease)
except antiphospholipid syndrome or Sjögren’s syndrome
were excluded from the study. Also, patients with
concomitant psoriasis or inflammatory disease (Crohn’s
disease or ulcerative colitis) were also excluded from the
study. A total of 907 patients with SLE were recruited for
the GWAS. Additional file 1: Table S1 summarizes the
main features of the Spanish GWAS cohort.
Healthy control individuals were also recruited
through the IMID Consortium as described previously
[15]. All controls were Caucasian and > 18 years old at
the time of recruitment. Individuals with one or more
grandparents born outside of Spain were excluded. Con-
trols with an autoimmune disease or with a family his-
tory of autoimmune disease were also excluded from
this cohort. A total of 1524 healthy control individuals
were finally included in the present GWAS. All the pro-
cedures were followed in compliance with the principles
of the Declaration of Helsinki and informed consent was
obtained from all participants. The study and the con-
sent procedure were reviewed and approved by the local
institutional review boards.
GWAS data from European-ancestry cohorts were ob-
tained from a recent meta-analysis [4]. For the present
study, GWAS association data were obtained from 4036
patients with SLE and 6959 controls of Caucasian European
ancestry. The details on the data quality control, imputation
and statistical association analyses have been previously de-
scribed [4]. Association data on a total of 37,577,690
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markers from the 22 autosomal chromosomes were avail-
able for meta-analysis.
Genotyping, quality control and imputation
In the Spain cohort, genome-wide genotyping was per-
formed using the Illumina Quad610 Beadchips (Illumina,
San Diego, CA, USA) at the National Genotyping Center
(CeGen, Madrid, Spain). This array genotyping platform
includes information on > 550,000 single nucleotide
polymorphisms (SNPs). A whole blood sample (5 mL)
was collected from all patients and genomic DNA
extracted using the Chemagic Magnetic Separation
Module I (PerkinElmer, Waltham, MA, USA). Genotyp-
ing was performed following the protocol recommended
by Illumina. Genotype calling was performed using the
GenomeStudio data analysis software v2011.1 (Illumina,
San Diego, CA, USA). Genotyping quality control was
performed using PLINK genomic analysis software [16].
Principal components of variation were estimated using
Eigensoft (v4.2) software [17]. The genomic inflation
factor was λGC = 1.16 in the European-ancestry GWAS,
and λGC = 1.06 in the Spain GWAS (Additional file 1:
Figure S2). After quality control analysis, 864 patients with
SLE and 1513 controls were available for imputation.
Genome-wide imputation was performed using GUID-
ANCE, an integrated framework for haplotype phasing
and genotype imputation of genotypes [18]. Markers and
samples were first tested for quality control. SNPs
with a genotyping call rate < 95% or a significant devi-
ation from Hardy-Weinberg equilibrium in controls
(p value ≤1 × 10− 6) were removed. Individuals with a
genotype call rate < 95% or outlier genetic background
(i.e. > 6 SD in any of the 10 principal components of
variation), were also excluded. After quality control,
pre-phasing of genotypes was performed using SHA-
PEIT2 [19] and genotype imputation using IMPUTE2.
The 1000G Phase1 integrated haplotypes was used as
the reference panel [20, 21].
A total of 30,038,143 markers were finally imputed from
the Spain GWAS cohort. From these, after filtering for
high imputation quality (info score > 0.8, n = 9,168,673)
and minor allele frequency (MAF) > 1%), 7,195,283
markers were available for GWAS. Association testing
was performed using the logistic regression model imple-
mented in SNPTEST v2 software adjusting for the first
two principal components of variation [22].
Meta-analysis of the common markers between the
two GWAS datasets was performed using METAL [23].
In this approach, z values are computed to summarize
both the direction of effect and the significance level for
each genetic marker. These z values are then combined
in a weighted sum that incorporates the sample size of
each cohort. The complete results from the Spain
GWAS and from the GWAS meta-analysis are available
for download at http://urr.cat/data/GWAS_SLE_summary-
Stats.zip. Association plots for each of the associated loci
were prepared using LocusZoom (http://locuszoom.org/).
Genome-wide pathway analysis
Several approaches are actually available to perform
pathway-based GWAS. However, most of these methods
do not account for the linkage disequilibrium (LD)
structure in the genome. The variable structure of LD,
particularly of highly correlated chromosomal regions
containing multiple genes, can negatively impact the re-
sults from genome-wide pathway analysis [24]. In order
to integrate this information into the pathway associ-
ation analysis, we used the method implemented in
PASCAL [25]. In this approach, genetic markers are first
mapped to genes in each pathway (here, all markers in-
side the gene ± 20 flanking kb). Correlated markers are
then identified using the LD structure estimated from a
reference population (in this study, from the Caucasian
European population from the 1000 Genomes Project
(1KG)). Combining the single-marker association values
with the LD structure, association scores are then com-
puted for all genes in the pathway. In those cases where
genes from the same pathway are located close in a
chromosome and in strong LD, a joint score is calcu-
lated. Finally, the scores of all genes within a pathway
are normalized, transformed and integrated to generate
a single association statistic that can be used to
determine the statistical significance of the association
between the pathway and the trait of interest. In this
study, the default parameter values were used, including
maximum number of SNPs per gene (n = 3000). The
SNP p value to gene score estimation was performed
using the sum gene score approach, and gene score
transforming into the pathway score was performed
using the chi-squared approach. The pathway analysis
method implemented in PASCAL has been shown to
perform better than other methods, particularly since it
has better control of type I error.
Pathways and their corresponding gene annotation
was obtained from the MSigDB molecular signatures re-
pository (http://software.broadinstitute.org/gsea/msigdb).
A total of 1077 biological pathways from the Reac-
tome (n = 674), Kyoto Expression of Genes and Ge-
nomes (n = 186) and BioCarta (n = 217) databases were
selected. The association p values obtained using PASCAL
in the two GWAS cohorts were combined using Fisher’s
method, and the significance was corrected for multiple
testing using Bonferroni’s adjustment.
In order to capture biologic pathways associated with
SLE through as yet unaccounted for genetic risk
variants, all regions previously associated with SLE risk
were removed from this analysis. For this objective, we
filtered out all markers within ± 250 kb distance from an
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established SLE risk SNP and with an LD r2 > 0.2. Given
the strong association between the HLA region and SLE




After quality control, a total of 7,195,283 autosomal
markers with MAF > 0.01 were available for association
testing in the Spain case-control cohort. From these,
7,110,321 variants were also present in the European
ancestry GWAS: 51 of the 52 previously known SLE risk
loci were in the same effect-size direction as originally
described. From these, 31 had nominal evidence of repli-
cation (p < 0.05, Additional file 1 Table S2). Four SNPs,
rs1270942 (HLA, OR (95% CI)Spain = 1.96 (1.59–2.42),
OR (95% CI)EUR = 2.53 (2.34–2.74), p value for hetero-
geneity (pHet) = 0.00074), rs494003 (RNASEH2C, OR
(95% CI)Spain = 1.44 (1.24–1.66), OR (95% CI)EUR = 1.16
(1.07–1.26); pHet = 0.0059), rs9652601 (CIITA-SOCS1,
OR (95% CI)Spain = 0.74 (0.66–0.85), OR (95% CI)EUR = 0.85
(0.8–0.9, pHet = 0.026), and rs3024505 (IL10, OR(95% CI)
Spain = 1.38 (1.17–1.62), OR (95% CI)EUR = 1.13 (1.04–1.22);
pHet = 0.028) showed evidence of heterogeneity between the
two GWAS cohorts.
Meta-analysis of the two GWAS cohorts identified five
new risk loci for SLE (Fig. 1, Table 1). None of the new
genome-wide significant loci showed evidence of hetero-
geneity of effect between the two cohorts (p > 0.05).
Three of the associated markers are SNPs in introns of
the genes encoding for growth factor receptor bound
protein 2 (GRB2, rs36023980), SET and MYND domain
containing 3 protein (SMYD3, rs1780813), and ST8
alpha-N-acetyl-neuraminide alpha-2,8-sialyltransferase 4
(ST8SIA4, rs55849330). Associated SNPs rs150518861
and rs114038709 are located in the flanking regions of
linker for activation of T cells family member 2 (LAT2)
and Rho GTPase activating protein 2 (ARHGAP27)
genes, respectively. Figure 2 shows the detailed associ-
ation results for each of the five new SLE risk loci.
Genetic pathway association study in SLE
After excluding the association signal from known risk
loci, pathway analysis identified 100 and 157 pathways
associated with SLE in the Spain and European-ancestry
cohorts, respectively, at the nominal level (p < 0.05).
From these, 30 pathways (3% of total) were found to be
associated in both cohorts, which is more than would be
expected by chance (p < 5 × 10− 4). After adjustment for
multiple testing, four biologic pathways were significantly
associated with SLE risk (Table 2).
Conditional and sex-specific association
In order to explore the presence of secondary signals
at each associated locus, we performed conditional
analysis in the Spain cohort. From all five loci, we
only identified one independent signal within 1 Mb of
the most strongly associated SNP that continued to
show evidence of association (conditional p < 1 × 10− 4).
This independent association was identified at the
GRB2 locus and maps to RNF157 gene (SNP
rs9891273, p = 4.99 × 10− 5, Additional file 1: Figure S3).
The presence of sex-specific associations was tested by
comparing the coefficients for SNP association estimated
Fig. 1 Manhattan plot of genome-wide association study meta-analysis results including the Spain cohort. Plot of the -log10 (p values) of
association between the 7,110,321 markers after meta-analysis between the European and Spain cohorts. The dashed horizontal line represents
the genome-wide significance threshold (p value = 5 × 10− 8). The known regions associated with systemic lupus erythematosus (SLE) risk and
genome-wide significant are colored in red. The five new genomic regions associated with SLE risk in this study are colored in green, with the
name of the corresponding gene above
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independently in women and men. We identified a
significant difference only for LAT2 SNP rs150518861
(p = 0.032). This risk variant was found to be more
strongly associated in the male cohort compared to the
female cohort.
Discussion
In the present study we have identified five new risk loci
for systemic lupus erythematosus. Performing a meta-
analysis on 4943 patients with SLE and 8483 controls
from different European ancestries, we have identified
variants at GRB2, SMYD3, ST8SIA4, LAT2, and ARH-
GAP27 loci associated with SLE susceptibility. At the
pathway level, we have also found four biological path-
ways associated with SLE risk independently of previ-
ously known risk genes.
In the present meta-analysis, we found an association
between an intronic SNP in the gene encoding for the
growth factor receptor-bound protein GRB2 and SLE
(rs36023980, p = 4.7 × 10− 9). Analysis of the tissue-
specific epigenetic data from the NIH Roadmap Epige-
nomics Project [26] for rs36023980 SNP showed a
strong regulatory activity in different immune cells, in-
cluding enhancer evidence in both T and B lymphocytes
(Additional file 1: Table S2). GRB2 encodes for a recep-
tor tyrosine-kinase (RTK) adaptor protein composed of
a single SH2 domain and two SH3 domains [27]. SLE is
a disease characterized by the activation of B cells that
recognize self-antigens via their B cell receptors (BCR).
In B cells, GRB2 functions as an expression adaptor
molecule, attenuating the signals that are transduced by
the BCR [28]. Together with Dok-3 and SHIP1, GRB2
forms a trimer protein complex that binds directly to
the BCR and prevents downstream signaling by inhibit-
ing PI3K signaling [29]. Gene expression at different
stages of B cell differentiation shows that GRB2 expres-
sion increases in more mature forms, particularly on
antigen-experienced memory B cells (Additional file 1:
Figure S4). Inadequate control of memory B cell differ-
entiation into plasma cells has been proposed as a trig-
ger for autoimmunity in SLE [30]. Our results therefore
are in line with the relevance of this causal disease
mechanism.
In a close functional relationship with GRB2, we also
found a significant association between linker for activa-
tion of T cells family member 2 gene (LAT2) locus and
SLE (rs150518861, p = 4.1 × 10− 8). LAT2 encodes for an
adaptor molecule that binds GRB2 and, therefore, is also
involved in BCR signaling [31]. The association at the
genetic level between SLE and two directly interacting
proteins strongly supports the implication of this
biological mechanism in SLE risk. B cell dysfunction is a
hallmark of SLE pathology [9], and our study supports
downstream regulation after antigen binding as a crucial
event in the disease etiology. In the evaluation of sex-
specific effects, we found this locus to be differentially
associated with SLE risk. The risk variant was associated
with SLE in men (p = 0.0074, β (95% CI) = 1.3 (0.25–2.2)),
and it was non-significant in women (p = 0.58, β
(95% CI) = 0.13 (− 0.33 to 0.62)). Previous studies
have shown that men require a higher genetic load
to develop the disease [32]. If replicated in an independent
cohort, this result would be in line with these findings,
confirming the importance of sex in mediating the effect
of some genetic risk factors in SLE. SMYD3 encodes for
an H3-Hk histone methyltransferase that has been associ-
ated with increased cell proliferation in cancer [33]. Al-
tered epigenetic patterns have been strongly associated
with SLE, mostly at the DNA level [34]. More recently,
however, methylated histones have also been identified as
targets of autoantibodies expressed in patients with SLE
[35]. Similar to other frequent nuclear autoantigens in
SLE, like double-stranded DNA or ribonucleoproteins,
methylated H3-Hk histones are able to trigger autoreac-
tive B cells after antigenic-exposure processes like apop-
tosis. According to the Roadmap Epigenomics Project
data, the associated SNP rs1780813 lies in a site that is
DNAse hypersensitive for > 30 different tissues, support-
ing its role in gene regulation.
To date little is known about the functional role of
SLE-associated genes STS8IA4 and ARHGAP27. In order
to infer the potential biological role of these two genes,
Table 1 Novel SNPs for SLE risk showing genome-wide significance (p < 5 × 10− 8) following meta-analysis of Spain and European
ancestry cohorts
European Spain Meta-analysis
Locus Chr SNP bp RA OR (CI 95%) p value OR (CI 95%) p value OR (CI 95%) p value
SMYD3 1 rs1780813 246,444,082 C 0.53 (0.40–0.69) 8.36 × 10−7 0.61 (0.37–0.98) 0.013 0.55 (0.31–0.79) 3.5 × 10−8
ST8SIA4 5 rs55849330 100,184,647 A 1.16 (1.10–.123) 8.4 × 10−7 1.14 (1.01–1.30) 0.019 1.16 (1.11–1.21) 4.9 × 10−8
LAT2 7 rs150518861 73,566,677 A 1.63 (1.34–1.99) 0.0000015 1.77 (1.23–2.56) 0.0074 1.66 (1.49–1.84) 4.1 × 10−8
ARHGAP27 17 rs114038709 43,456,728 T 1.15 (1.08–1.22) 0.0000012 1.20 (1.07–1.35) 0.0088 1.16 (1.11–1.22) 3.7 × 10−8
GRB2 17 rs36023980 73,341,284 C 1.18(1.11–1.25) 0.0000015 1.23 (1.08–1.40) 0.00039 1.18 (1.13–1.24) 4.7 × 10−9
OR are shown for the minor allele for all five associated polymorphisms
Locus closest gene, Chr chromosome, SNP single nucleotide polymorphism, bp base pair, RA risk allele, OR odds ratio
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Fig. 2 Regional association plots from the meta-analysis of the two cohorts for all five genome-wide significant loci: -log10 (p values) for both
directly genotyped and imputed single nucleotide polymorphisms (SNPs) are plotted as a function of genomic position (NCBI Build 37). The
purple diamond indicates the lead SNP at each locus; the remaining markers are colored based on the LD (r [2]) in relation to the lead SNP.
Underlying the image, the estimated recombination rate (cM/Mb) for the CEU panel from 1000 Genomes is depicted
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we used the GeneNetwork approach, a functional-inference
method based on the gene co-expression patterns extracted
from microarray data from > 80,000 samples [36]. With this
approach, we found strong evidence that STS8IA4 is in-
volved in T cell activation (p value = 2.7 × 10− 13,
Additional file 2: Table S4), and that ARHGAP27 is
implicated in mitogen-activated protein kinase (MAPKi-
nase) signaling (p value = 3.33 × 10− 8, Additional file 2:
Table S5). Both biological processes have been previously
associated with SLE etiology, and our results not only
support their involvement in disease risk but also
suggest new gene functions. Furthermore, expression
Table 2 Biological pathways significantly associated with SLE risk
Biological pathway N genes Spain cohort p value European cohort p value Combined p value Adjusted p value
B cell receptor signaling 75 0.016 2.05 × 10−6 5.28 × 10− 6 0.0057
CTLA4 co-stimulatory signal during T-cell activation 21 0.0014 0.0016 3.06 × 10−5 0.033
Interleukin-4 signaling 11 0.00029 0.01 3.97 × 10−5 0.043
Cell surface interactions at the vascular wall 91 0.0057 0.0006 4.63 × 10−5 0.049
Biological pathways significantly associated with systemic lupus erythematosus (SLE) after meta-analysis of the Spain and Caucasian European cohorts. P values for
each cohort were estimated using PASCAL after removing the previously known risk loci for SLE
N genes number of genes in the pathway
Table 3 Top single-marker hits in genes from the four genetic pathways associated with SLE
Gene Marker Chr bp MA OR p (Spain) p (EUR) p (meta) Pathway
BCL10 rs12084253 1 85,720,326 T 1.11 0.020 0.0015 0.00012 BCR
FCER1G rs1136224 1 161,184,097 G 0.91 0.023 0.022 0.0024 VASC
FCGR2B rs182968886 1 161,642,985 A 0.86 0.044 0.0018 0.00023 BCR
CD247 rs113305799 1 167,416,006 A 1.17 0.0035 0.044 0.0022 CTLA4
PROC rs6740067 2 128,156,366 T 1.16 0.043 0.018 0.0026 VASC
CTLA4 rs733618 2 204,730,944 C 1.19 0.026 0.0018 0.00016 CTLA4
PPP3CA rs13120190 4 102,056,663 G 0.93 0.025 0.047 0.0060 BCR
IL2 rs45522533 4 123,396,876 T 1.16 0.016 0.0058 0.00044 CTLA4
SLC7A11 rs74843273 4 139,150,464 T 0.81 0.025 0.0066 0.00065 VASC
ITK rs60714766 5 156,602,589 T 1.07 0.015 0.043 0.0042 CTLA4
CARD11 rs6461796 7 3,071,195 C 0.94 0.027 0.033 0.0042 BCR
LYN rs17812659 8 56,889,862 G 0.86 0.013 2.57E-05 1.17E-06 BCR,VASC
ANGPT1 rs79847080 8 108,293,443 G 0.84 0.032 0.0028 0.00031 VASC
VAV2 rs2810536 9 136,812,625 G 1.08 0.030 0.011 0.0013 BCR
KRAS rs17388587 12 25,389,220 G 1.13 0.036 0.048 0.0075 BCR, VASC
PRKCB rs11641223 16 24,020,316 T 1.11 0.041 0.0010 0.00012 BCR
CD19 16:28955702:D 16 28,955,702 I 1.06 0.0077 0.047 0.0034 BCR
SLC7A6 rs55856208 16 68,324,210 T 1.08 0.045 0.049 0.0086 VASC
PLCG2 rs11548656 16 81,916,912 G 1.3 0.014 0.00062 0.000035 BCR
ATP1B2 rs1794287 17 7,578,837 A 0.9 0.023 0.024 0.0026 VASC
ITGB3 rs75211989 17 45,366,261 G 1.11 0.00014 0.020 0.00020 VASC
GRB2 rs36023980 17 73,341,284 T 0.85 0.00039 1.51E-06 4.73E-09 CTLA4, IL4, BCR, VASC
NFATC1 rs111354805 18 77,238,078 T 1.21 0.027 6.58E-05 5.26E-06 BCR
MAP2K2 rs350913 19 4,096,779 T 0.94 0.029 0.030 0.0039 BCR
CD79A rs16975619 19 42,392,441 C 1.52 0.020 0.0099 0.00089 BCR
SIRPG rs11696739 20 1,600,925 A 0.92 0.044 0.0050 0.00069 VASC
RAC2 rs229566 22 37,602,131 A 1.06 0.041 0.03 0.0047 BCR
Suggestive risk variants were identified as those markers showing with the most significant meta-analysis p value (p (meta)), and that are associated in the two
genome-wide association study cohorts (p < 0.05) and show the same direction of effect (OR) MA minor allele, OR odds ratio according to minor allele in European
ancestry cohort, I insertion allele, Pathway biological pathway/s where the gene has been annotated, BCR B cell receptor pathway, CTLA4 CTLA4 pathway, IL4
interleukin-4 pathway, VASC vascular cell wall pathway
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quantitative trait locus (eQTL) evidence supports that
both SNPs regulate expression of the corresponding
genes in cis. Whole blood eQTL analysis [37] shows a
strong association between variation at rs114038709
and ARHGAP27 expression (p = 4.1 × 10− 134), and the
most significant eQTL evidence for rs55849330 is
associated to STS8IA4 expression in immortalized B
cells [38] (p = 5.6 × 10− 10).
Using a pathway-based analysis we have identified
four biological pathways associated with SLE. Since
the objective was to identify new genetic risk vari-
ation for SLE, our approach excluded all association
signals from previously known SLE genes. We showed
that by using biological pathway knowledge, it is still
possible to capture genetic variation that is relevant
for the disease. One limitation of this approach is
that it relies on the specific knowledge of gene func-
tions and pathway definitions, which is still relatively
low for a substantial fraction of the genome [39]. An-
other limitation is that pathway association is per-
formed on variants within or close to genes. Distant
cis regulation and also trans regulation variants are
also plausible mechanisms of action [40]. With better
knowledge of regulatory effects, particularly on iso-
lated cell types, pathway-based analysis will become
an even more powerful approach to detect the miss-
ing disease heritability. Despite these limitations, our
results are robust since they are based on strongly
supported biological knowledge. Also, we provide stat-
istical evidence of pathway association from two inde-
pendent GWAS cohorts which, to our knowledge, has
not been previously performed in SLE.
The BCR signaling pathway had the strongest associ-
ation with SLE. This result is in agreement with the re-
sults found at the single-marker level, where variants at
BCR signaling genes GRB2 and LAT2 were found to be
associated with disease susceptibility. Within the BCR
signaling pathway, however, there are multiple other
single-marker hits in other genes indicating nominally
significant association with disease susceptibility in both
cohorts. Given that they belong to an associated bio-
logical pathway, these signals are strongly suggestive risk
variants for SLE (Table 3). Of relevance, several of the
proteins encoded by the genes in this pathway, like BTK
or CTLA4, are currently being evaluated as therapeutic
targets for SLE [41, 42]. Finding an efficacious treatment
in SLE has proven extremely difficult and our results
support the importance of targeting this pathway. Gen-
etic evidence, either direct or through associated gene
networks, has been shown to improve drug efficacy pre-
diction [43]. Based on the association signals found in
the two cohorts, for example, the proteins encoded by
LYN (p = 1.17 × 10− 6) and NFATC1 (p = 5.26 × 10− 6)
could also be considered as new drug targets for SLE.
Two other associated pathways - the CTLA4 co-
stimulatory signal and IL4 pathways - are strongly
related to B cell activation. CTLA4 is a co-inhibitory
molecule expressed on activated helper T - TH2 and fol-
licular - cells. Inhibition of CTLA4 increases B cell acti-
vation after antigen binding, resulting in the production
of antibodies [44]. IL-4 is a cytokine that is also
expressed in helper T cells and it is essential in the acti-
vation of antigen-bound naïve B cells. Similar to the
BCR signaling pathway, these two genetically associated
biological processes that are deeply related to B cell acti-
vation could be the source of new effective drug targets
for the disease [45]. In this regard, a fusion protein in-
cluding the extracellular domain of CTLA4 (abatacept)
is being currently evaluated as a therapy for more severe
forms of SLE [46].
Conclusions
In the present study we have performed a GWAS meta-
analysis approach to identify new genetic variation in SLE.
We have found five new genome-wide significant risk loci
and four biologic pathways associated with SLE risk.
Single-marker associations involve BCR downstream sig-
naling mechanisms with disease susceptibility, and auto-
antigen generation and immune cell activity regulation.
Pathway-based analysis confirmed the relevance of BCR
signaling pathway and other B cell activation mechanisms
in the disease etiology. The results from this study signifi-
cantly expand the knowledge of the biological processes
implicated in susceptibility to SLE.
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